vimarsana.com
Home
Live Updates
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs : vimarsana.com
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs : vimarsana.com
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
CAMBRIDGE, Mass., Oct. 24, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...
Related Keywords
Boston ,
Massachusetts ,
United States ,
Dublin ,
Ireland ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Steve Bellon ,
Danette Daniels ,
Hans Vitzthum ,
Michael Lampe ,
J Andrew Livington ,
Mike Collins ,
Karin Hellsvik ,
Greg Dearborn ,
Connective Tissue Oncology Society Annual Meeting ,
Exchange Commission ,
Drug Discovery Development Look Like ,
Linkedin ,
Nasdaq ,
Foghorn Therapeutics Inc ,
Therapeutics Inc ,
Clinical Development ,
Biology Research Portfolio Strategy ,
Connective Tissue Oncology Society ,
Md Anderson Cancer Center ,
Twitter ,
Company Annual Report On Form ,
Annual Targeted Protein Degradation ,
Chief Scientific Officer ,
Vice President ,
Protein Degradation Platform ,
Foghorn Therapeutics ,
Keynote Plenary ,
What Does ,
Development Look ,
Laura La Bonte ,
Senior Director ,
Research Portfolio Strategy ,
Senior Scientist ,
Gene Traffic ,
Annual Report ,
Lifesci Advisors ,
Markets ,